The Transcription Factor T-Bet Is Regulated by MicroRNA-155 in Murine Anti-Viral CD8 + T Cells via SHIP-1

We report here that the expression of the transcription factor T-bet, which is known to be required for effector cytotoxic CD8 T lymphocytes (CTL) generation and effector memory cell formation, is regulated in CTL by microRNA-155 (miR-155). Importantly, we show that the proliferative effect of miR-1...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology Vol. 8; p. 1696
Main Authors: Hope, Jennifer L, Stairiker, Christopher J, Spantidea, Panagiota I, Gracias, Donald T, Carey, Alison J, Fike, Adam J, van Meurs, Marjan, Brouwers-Haspels, Inge, Rijsbergen, Laurine C, Fraietta, Joseph A, Mueller, Yvonne M, Klop, Rosemarieke C, Stelekati, Erietta, Wherry, E John, Erkeland, Stefan J, Katsikis, Peter D
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 06-12-2017
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report here that the expression of the transcription factor T-bet, which is known to be required for effector cytotoxic CD8 T lymphocytes (CTL) generation and effector memory cell formation, is regulated in CTL by microRNA-155 (miR-155). Importantly, we show that the proliferative effect of miR-155 on CD8 T cells is mediated by T-bet. T-bet levels in CTL were controlled by miR-155 SH2 (Src homology 2)-containing inositol phosphatase-1 (SHIP-1), a known direct target of miR-155, and SHIP-1 directly downregulated T-bet. Our studies reveal an important and unexpected signaling axis between miR-155, T-bet, and SHIP-1 in CTL responses and suggest an important signaling module that regulates effector CTL immunity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Bernard Malissen, UMR7280 Centre d’immunologie de Marseille-Luminy (CIML), France
Specialty section: This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology
Reviewed by: Abdelhadi Saoudi, Institut National de la Santé et de la Recherche Médicale, France; Toshinori Nakayama, Chiba University, Japan; Dietmar Zehn, Swiss Vaccine Research Institute, Switzerland
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2017.01696